These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7535458)

  • 21. The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer.
    Demetri GD
    Pharmacotherapy; 1996; 16(3 Pt 2):94S-100S. PubMed ID: 8726588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of peripheral stem cells collected and transplanted in combination with granulocyte-macrophage and granulocyte colony-stimulating factors.
    Handgretinger R; Klingebiel T; Herter M; Lang P; Gisselhart A; Dopfer R; Scheel-Walter H; Ehrlich H; Niethammer D
    Prog Clin Biol Res; 1994; 389():479-86. PubMed ID: 7535457
    [No Abstract]   [Full Text] [Related]  

  • 23. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective comparison of three different methods for mobilization of peripheral blood stem cells.
    Mangan KF; Mullaney MT; Klumpp TR; Goldberg SL; Macdonald JS
    Prog Clin Biol Res; 1994; 389():441-8. PubMed ID: 7535452
    [No Abstract]   [Full Text] [Related]  

  • 25. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation.
    Schröder CP; Wisman GB; de Jong S; van der Graaf WT; Ruiters MH; Mulder NH; de Leij LF; van der Zee AG; de Vries EG
    Br J Cancer; 2001 May; 84(10):1348-53. PubMed ID: 11355946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
    Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
    Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: immunologic consequences affecting clinical outcome.
    Chakraborty N; Bilgrami S; Maness L; Guo C; Perez-Diez A; Mukherji B; Tutschka P
    Bone Marrow Transplant; 1999 Oct; 24(8):837-43. PubMed ID: 10516693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yield of primed progenitor cells as determined by days of priming with recombinant human granulocyte-colony stimulating factor.
    Ericson SG; Meehan KR; Tosteson TD; Mills LE
    Prog Clin Biol Res; 1994; 389():449-55. PubMed ID: 7535453
    [No Abstract]   [Full Text] [Related]  

  • 29. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
    Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
    J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
    Myers SE; Mick R; Williams SF
    Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer.
    Vaughan WP; Reed EC; Edwards B; Kessinger A
    Bone Marrow Transplant; 1994 May; 13(5):619-24. PubMed ID: 7914447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
    Martín M; Casado A; Llorente L; López Martín JA; Rodríguez Lescure A; Nieto Y; Ayala F; Pérez Calvo J; Alonso JL; Pérez López C; Villegas A; Díaz-Rubio E
    Med Clin (Barc); 1997 Dec; 109(20):775-81. PubMed ID: 9493155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
    Ford C; Spitzer G; Reilly W; Adkins D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-81-S17-86. PubMed ID: 9374101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mobilization of peripheral blood stem cells: comparing cyclophosphamide and growth factor based regimens.
    Janssen WE; Smilee R; Carter R; Rahn D; Cairo M; Hiemenz JH; Zorsky PE; Fields KK; Ballester O; Perkins J
    Prog Clin Biol Res; 1994; 389():429-39. PubMed ID: 7700915
    [No Abstract]   [Full Text] [Related]  

  • 35. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.
    Roman-Unfer S; Bitran JD; Garrison L; Proeschel C; Hanauer S; Schroeder L; Johnson L; Klein L; Martinec J
    Exp Hematol; 1996 Jun; 24(7):823-8. PubMed ID: 8647233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
    Shi Y; Pan F; Han X
    Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [High-dosage chemotherapy and autologous transplant of hematopoietic germ cells from peripheral blood in high-risk recurrence carcinoma of the breast (with >= or 10 involved axillary nodes at diagnosis) Preliminary results of the Solti 9301 cooperative study].
    Solano C; Sola C; Lluch A; Hornedo J; López J; Cortés-Funes H; García-Conde J
    Sangre (Barc); 1997 Apr; 42 Suppl 1():53-6. PubMed ID: 9381304
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
    J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
    Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.